US 11,939,346 B2
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
Derek John Londesbrough, Hartlepool (GB); Christopher Brown, Gateshead (GB); Julian Scott Northen, South Shields (GB); Gillian Moore, Sedgefield (GB); Hemant Kashinath Patil, Surrey (GB); and David E. Nichols, Chapel Hill, NC (US)
Assigned to Compass Pathfinder Limited, Altrincham (GB)
Filed by Compass Pathfinder Limited, Altrincham (GB)
Filed on Apr. 17, 2023, as Appl. No. 18/135,265.
Application 18/135,265 is a continuation of application No. 17/886,204, filed on Aug. 11, 2022, granted, now 11,629,159.
Application 17/886,204 is a continuation of application No. 17/531,159, filed on Nov. 19, 2021, granted, now 11,447,510, issued on Sep. 20, 2022.
Application 17/531,159 is a continuation of application No. 17/228,936, filed on Apr. 13, 2021, granted, now 11,180,517, issued on Nov. 23, 2021.
Application 17/228,936 is a continuation of application No. 17/172,411, filed on Feb. 10, 2021, granted, now 11,149,044, issued on Oct. 19, 2021.
Application 17/172,411 is a continuation of application No. 17/116,739, filed on Dec. 9, 2020, granted, now 10,954,259, issued on Mar. 23, 2021.
Application 17/116,739 is a continuation of application No. 16/920,223, filed on Jul. 2, 2020, granted, now 10,947,257, issued on Mar. 16, 2021.
Application 16/920,223 is a continuation of application No. 16/679,009, filed on Nov. 8, 2019, granted, now 11,505,564, issued on Nov. 22, 2022.
Application 16/679,009 is a continuation of application No. 16/155,386, filed on Oct. 9, 2018, granted, now 10,519,175, issued on Dec. 31, 2019.
Claims priority of application No. 1716505 (GB), filed on Oct. 9, 2017; application No. 1810588 (GB), filed on Jun. 28, 2018; and application No. 1816438 (GB), filed on Oct. 9, 2018.
Prior Publication US 2023/0250115 A1, Aug. 10, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 209/16 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01); C07F 9/572 (2006.01)
CPC C07F 9/5728 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2054 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); C07D 209/16 (2013.01); C07B 2200/13 (2013.01)] 28 Claims
 
1. Crystalline psilocybin characterized by X-ray powder diffraction (XRPD) peaks at 17.5±0.1 and 19.7±0.1° 2θ, wherein the crystalline psilocybin has a chemical purity of greater than 97% as determined by high-performance liquid chromatography (HPLC) analysis.